146 related articles for article (PubMed ID: 38470132)
41. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
Saavedra D; Crombet T
Front Immunol; 2017; 8():269. PubMed ID: 28348561
[TBL] [Abstract][Full Text] [Related]
42. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
[TBL] [Abstract][Full Text] [Related]
44. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
45. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
Schaedler E; Remy-Ziller C; Hortelano J; Kehrer N; Claudepierre MC; Gatard T; Jakobs C; Préville X; Carpentier AF; Rittner K
Vaccine; 2017 Jan; 35(4):577-585. PubMed ID: 28012777
[TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.
Mountzios G; Linardou H; Kosmidis P
Ann Transl Med; 2016 Jul; 4(14):268. PubMed ID: 27563655
[TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.
Zhou L; Wang XL; Deng QL; Du YQ; Zhao NQ
Sci Rep; 2016 Aug; 6():32020. PubMed ID: 27558285
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
[TBL] [Abstract][Full Text] [Related]
50. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K; Sugawara S; Saijo Y; Maemondo M; Sato A; Takamori S; Harada T; Sasada T; Kakuma T; Kishimoto J; Yamada A; Noguchi M; Itoh K; Nakanishi Y
J Immunol Res; 2016; 2016():1745108. PubMed ID: 27274999
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy for lung cancer: advances and prospects.
Yang L; Wang L; Zhang Y
Am J Clin Exp Immunol; 2016; 5(1):1-20. PubMed ID: 27168951
[TBL] [Abstract][Full Text] [Related]
52. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
54. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Goldstraw P; Chansky K; Crowley J; Rami-Porta R; Asamura H; Eberhardt WE; Nicholson AG; Groome P; Mitchell A; Bolejack V; ;
J Thorac Oncol; 2016 Jan; 11(1):39-51. PubMed ID: 26762738
[TBL] [Abstract][Full Text] [Related]
55. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
[TBL] [Abstract][Full Text] [Related]
56. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.
Saavedra D; García B; Lorenzo-Luaces P; González A; Popa X; Fuentes KP; Mazorra Z; Crombet T; Neninger E; Lage A
Cancer Immunol Immunother; 2016 Jan; 65(1):37-45. PubMed ID: 26589409
[TBL] [Abstract][Full Text] [Related]
57. Cancer and the Immune System: Basic Concepts and Targets for Intervention.
Pardoll D
Semin Oncol; 2015 Aug; 42(4):523-38. PubMed ID: 26320058
[TBL] [Abstract][Full Text] [Related]
58. Lung cancer: Biology and treatment options.
Lemjabbar-Alaoui H; Hassan OU; Yang YW; Buchanan P
Biochim Biophys Acta; 2015 Dec; 1856(2):189-210. PubMed ID: 26297204
[TBL] [Abstract][Full Text] [Related]
59. Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
Rotonda C; Anota A; Mercier M; Bastien B; Lacoste G; Limacher JM; Quoix E; Bonnetain F
PLoS One; 2015; 10(7):e0132568. PubMed ID: 26207902
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.
Wang M; Cao JX; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
BMJ Open; 2015 Apr; 5(4):e006321. PubMed ID: 25872936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
